Impact of COVID-19 Pandemic on Advanced Non-small Cell Lung Cancer Treatment at a Japanese Hospital.
Cancer Diagn Progn
; 3(6): 716-720, 2023.
Article
en En
| MEDLINE
| ID: mdl-37927803
ABSTRACT
Background/Aim:
The COVID-19 pandemic has forced medical institutions to scale back their practice. Changes in patient behavior seemed to be having an impact. We conducted a survey with the aim of reviewing lung cancer treatment during the pandemic period and identifying problems. Patients andMethods:
We examined the medical records of all patients pathologically diagnosed with non-small cell lung cancer (NSCLC) in our hospital from 2017 to 2022. NSCLC patients were divided into two groups those diagnosed between 2017 and 2019 (first period) and those diagnosed between 2020 and 2022 (second period).Results:
Within the study period, 267 NSCLC patients (first period 147 patients, second period 121 patients) were diagnosed in our hospital. The patients in the two study periods did not differ significantly in age (p=0.613), ECOG performance status (p=0.125), and clinical stage (p=0.354). Tumor size was significantly larger in the second period with a mean of 5.88 cm ± 3.02, compared to 4.24 cm ± 1.76 in the first period (p<0.001). In the standard treatment group, the median survival time was 457 days in the first period and 313 days in the second period (p=0.063). In the best supportive care group, median survival time was 122 days in the first period and 57 days in the second period (p=0.004).Conclusion:
Patients themselves refrained from seeking consultation for lung cancer treatment during the pandemic period. It is inconclusive how to reduce the delay due to the suppression of consultations, but this is an important issue for the future.
Texto completo:
1
Base de datos:
MEDLINE
Idioma:
En
Revista:
Cancer Diagn Progn
Año:
2023
Tipo del documento:
Article